Conagen was founded on a simple but transformative belief, nature has already solved many of the problems modern industries are still trying to address. The challenge is not inventing entirely new chemistry, but learning how to access, scale, and optimize what nature has already evolved over hundreds of millions of years. Established in 2010 in St. Louis, Missouri, Conagen emerged fromthe intersection of plant biology research and industrial ingredient expertise. Its founders recognized a fundamental limitation in traditional supply chains. Extracting valuable compounds directly from plants was not only resource-intensive but also unsustainable at scale. As Dr. Yisheng Wu, the company’s VP of Flavors and Fragrances explains, the goal was to move “from sourcing and extracting from nature” to engineering those same metabolic pathways into microorganisms, enabling production through precision fermentation.

Four years after its founding, Conagen relocated its headquarters to the Boston area, positioning itself within one of the world’s leading biotechnology hubs. The move provided access to talent, partnerships, and a vibrant ecosystem that would help accelerate the company’s growth. Over the past decade, Conagen has built four core technology platforms—terpenoids, polyphenols, fatty acid derivatives, and peptides—forming the foundation of its synthetic biology capabilities. At the heart of Conagen’s agricultural vision is a philosophy the Dr. Wu describes as “learning from nature, scaling from nature.” Plants, unlike animals, cannot escape environmental threats. Over evolutionary time, they have developed sophisticated chemical defense systems to combat insects, microbial pathogens, drought, and UV stress. These phytochemicals represent a vast and largely untapped resource in modern agriculture.

“We believe that nature molecules hold immense potential to address agriculture challenges,” Dr. Wu says. “From crop resilience to sustainable plant protection strategies, Conagen sees an opportunity to unlock, optimize, and industrialize these compounds through synthetic biology.” By engineering plant biosynthetic pathways into microorganisms, the company produces high-value natural molecules in controlled fermentation systems, making them economically viable and scalable. This approach directly addresses several challenges faced by agricultural innovators. Many promising compounds identified in plants exist only in trace amounts, making extraction impractical. Traditional chemical synthesis can produce similar molecules but often results in mixtures of stereoisomers—different structural forms of the same compound—that reduce bioactivity and complicate purification. Separating these forms chemically is expensive and inefficient.

In fact, Conagen’s fermentation-based production mimics nature’s precision. Instead of generating mixed chemical outputs, the company engineers’ microorganisms to produce specific stereochemical configurations. “What we produce is stereochemistry-specific,” Dr. Wu explains, resulting in higher purity, greater bioactivity, and reduced byproducts. For customers, this means more effective ingredients and more consistent performance.

Precision fermentation also decouples production from climate and geography. Plant-derived compounds often depend on seasonal harvests or specific growing regions. Poor weather or supply chain disruptions can limit availability. By producing molecules in fermenters, Conagen ensures consistent supply regardless of environmental conditions. This independence is particularly valuable in agriculture, where resilience and reliability are critical. The company’s development pipeline reflects an integrated engineering mindset. Each project begins with identifying a target molecule. Conagen then designs and engineers a microbial strain capable of producing that compound by introducing and optimizing the necessary biosynthetic enzymes. The process is iterative—build, test, learn, redesign—guided by extensive data collection at every stage.

Once a productive strain is developed, fermentation conditions are optimized and scaled, moving from small laboratory volumes to larger bioreactors. Downstream processing purifies the target compound from the fermentation broth. The entire workflow, from strain engineering to purification, is managed internally. This vertical integration is one of Conagen’s defining differentiators. Unlike many biotechnology firms that specialize in either upstream strain development or downstream manufacturing, Conagen operates as a one-stop platform. “We have the capability from strain development all the way to manufacturing,” Dr. Wu explains. This integrated model allows customers to move quickly from concept to tangible product.

One practical advantage of this structure is flexibility in sample delivery. Agricultural and food companies often need small quantities of novel compounds to conduct preliminary testing. Working across multiple vendors can delay progress, as each stage must reach a certain level of optimization before moving forward. Conagen can provide gram-scale samples early in development, even before full-scale optimization is complete. While initial costs may be higher, the speed enables customers to de-risk their projects and validate efficacy sooner.

A case in point involves a customer that identified a promising agricultural compound with strong preliminary results. Natural yield was extremely low, and chemical synthesis produced multiple stereochemical variants, diminishing performance. Conagen engineered a microbial strain incorporating the biosynthetic pathway to selectively produce the precise stereochemical form required. By optimizing both the strain and fermentation process, the company achieved scalable production with improved purity and consistency, delivering exactly what the customer needed.

Although Conagen’s agricultural programs remain largely confidential, the company’s broader capabilities are illustrated by its flagship sugar reduction initiative. Stevia leaves contain multiple sweet compounds, including trace steviol glycosides with desirable taste profiles and more abundant steviol glycosides that produce undesirable aftertaste. Traditional extraction yields low amounts and purity of the preferred steviol glycosides. Through synthetic biology and fermentation, Conagen produces individual steviol glycosides, allowing precise formulation. Over years of iterative optimization, the company reduced production costs by orders of magnitude, demonstrating the economic viability of its platform.

Looking ahead, Conagen sees enormous potential in its accumulated molecular library. Over more than a decade, the company has built and tested far more pathways than it has commercialized. Today, Some molecules developed years ago are being requested by customers as new markets and applications emerge. Through partnerships across the agricultural and ingredient value chain, companies can leverage Conagen’s experience, strain engineering capabilities, and pathway portfolio to accelerate the development of new bio-based solutions. With research operations in Massachusetts and manufacturing capabilities in Europe and Asia, Conagen operates on a global scale.

“We truly believe our fundamental philosophy is coming from nature,” Dr. Wu concludes.